Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | IDH1 | O75874 | 10/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4927875 | 0.90 | LRRK2 (0.49) | LRRK2MAPTPLAUTP53IDH1 | |
| SCHEMBL4921833 | 0.89 | LRRK2 (0.50) | LRRK2MAPTTP53IDH1 | |
| SCHEMBL4919479 | 0.86 | LRRK2 (0.49) | LRRK2MAPTIDH1 | |
| SCHEMBL4931043 | 0.85 | LRRK2 (0.49) | LRRK2MAPTIDH1 | |
| SCHEMBL4919058 | 0.82 | LRRK2 (0.48) | LRRK2MAPTTP53IDH1THRB | |
| SCHEMBL4939783 | 0.82 | LRRK2 (0.44) | LRRK2MAPTPLAUTP53IDH1 | |
| SCHEMBL4918838 | 0.79 | LRRK2 (0.44) | LRRK2MAPTTP53IDH1 | |
| SCHEMBL4919051 | 0.79 | LRRK2 (0.48) | LRRK2MAPTTP53 | |
| SCHEMBL4928886 | 0.79 | LRRK2 (0.53) | LRRK2 | |
| SCHEMBL4923074 | 0.78 | LRRK2 (0.46) | LRRK2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | NOVO NORDISK A/S (DK) | 2008-11-06 | — | — | US | disclosed |
| EP-1765814-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006003096-A1 | CONDENSED THIOPHENE DERIVATIVES AND THEIR USE AS CYCLIC GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275066-A1 | Condensed Thiophene Derivatives and Their Use as Cyclic Glp-1 Agonists | GLP1R, GIPR, GCGR | LRRK2 327/4885MAPT 4242/4885PLAU 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.